• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Eyenovia Inc.

Eyenovia enrolls first patient in Phase 3 trial for treating presbyopia

November 4, 2021 By Sean Whooley

Eyenovia (NSDQ:EYEN) announced today that it enrolled the first patient in the second Phase 3 clinical trial for its MicroLine formulation. New York-based Eyenovia designed its MicroLine proprietary pilocarpine formulation for temporary improvement in near vision (presbyopia). Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Clinical Trials, Drug Pumps, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceutical Tagged With: Eyenovia Inc.

Eyenovia appoints Dr. Julia Haller to board of directors

April 1, 2021 By Sean Whooley

Eyenovia (NSDQ:EYEN) announced today that it appointed renowned ophthalmologist Dr. Julia Haller to its board of directors. New York–based Eyenovia adds the experienced Haller to its board as it continues to develop the MydCombi fixed-combination mydriatic agent for potential use in comprehensive eye exams with a formulation for touchless fixed-combination microdosing to improve the patient […]

Filed Under: Business/Financial News, Drug-Device Combinations, Optical/Ophthalmic Tagged With: Eyenovia Inc., Personnel Moves

Eyenovia partners with Eversana to commercialize pupil dilation agent

March 23, 2021 By Sean Whooley

Eyenovia (NSDQ:EYEN) announced today that it partnered with Eversana to help commercialize MydCombi if it earns U.S. approval. MydCombi is a fixed-combination mydriatic agent for potential use in comprehensive eye exams with a formulation for touchless fixed-combination microdosing in an effort to improve the patient experience. The FDA earlier this month accepted Eyenovia’s New Drug Application […]

Filed Under: Business/Financial News, Contract Manufacturing, Drug-Device Combinations, Optical/Ophthalmic Tagged With: Eversana, Eyenovia Inc.

Eyenovia touts study of pupil dilation treatment

March 17, 2021 By Sean Whooley

Eyenovia (NSDQ:EYEN) today announced positive results from a study of its microdose array print (MAP) pupil dilation technology. Study data, published in Therapeutic Delivery, revealed pooled results from two prospective, double-masked, controlled, cross-over superiority Phase 3 studies. Those results concluded that a micro-dosed fixed-combination of tropicamide 1% and phenylephrine 2.5% for pupil dilation (mydriasis) is safe and […]

Filed Under: Clinical Trials, Drug-Device Combinations, Optical/Ophthalmic, Pharmaceutical Tagged With: Eyenovia Inc.

FDA accepts New Drug Application for Eyenovia pupil dilation tech

March 2, 2021 By Sean Whooley

Eyenovia (NSDQ:EYEN) announced today that the FDA accepted its New Drug Aplication for its MydCombi pupil dilation agent. MydCombi is a fixed-combination mydriatic agent for potential use in comprehensive eye exams with a formulation for touchless fixed-combination microdosing in an effort to improve the patient experience, according to a news release. Get the full story at […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Regulatory/Compliance Tagged With: Eyenovia Inc., FDA, New Drug Application (NDA)

Eyenovia kicks off second Ph3 trial for pupil dilation tech

December 4, 2018 By Sarah Faulkner

Eyenovia (NSDQ:EYEN) said this week that it finished patient enrollment in its Phase III Mist-1 trial and enrolled the first patient in its second Phase III trial for the company’s combination eye solution delivered as a micro-dose using its Optejet device. The company is studying the therapy for pharmacologic mydriasis – pupil dilation for eye exams. […]

Filed Under: Clinical Trials, Drug-Device Combinations, Optical/Ophthalmic, Pharmaceutical, Wall Street Beat Tagged With: Eyenovia Inc.

Eyenovia touts publication of intraocular pressure data for micro-dose tech

November 29, 2018 By Sarah Faulkner

Eyenovia (NSDQ:EYEN) said this week that the results of its Phase II PG21 study were published in the Nov. issue of the journal Clinical Ophthalmology. The New York-based company’s Phase II study evaluated the effect of self-administered micro-dose latanoprost on intraocular pressure. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Clinical Trials, Drug-Device Combinations, Optical/Ophthalmic, Pharmaceutical, Wall Street Beat Tagged With: Eyenovia Inc.

Eyenovia launches Ph3 trial for pupil dilation tech

November 26, 2018 By Sarah Faulkner

Eyenovia (NSDQ:EYEN) said today that it enrolled the first patient in the first of two Phase III trials of the company’s MicroStat program. The Mist-1 and Mist-2 trials are slated to study the safety and efficacy of the company’s 2.5% phenylephrine, 1% tropicamide eye solution, delivered as a micro-dose using the Optejet device. Get the full […]

Filed Under: Clinical Trials, Drug-Device Combinations, Optical/Ophthalmic, Pharmaceutical, Wall Street Beat Tagged With: Eyenovia Inc.

20 medical device startups you need to know

April 13, 2018 By Chris Newmarker

There’s a lot of excitement these days around digital health. But there are actually many medical device startups out there in other spaces that continue to push the overall boundaries of medtech. From neuromodulation to drug delivery, surgical robotics and more, here’s a roundup of 20 medical device startups catching the eye of Medical Design […]

Filed Under: Business/Financial News, Cardiovascular, Drug-Device Combinations, Neuromodulation/Neurostimulation, News Well, Surgical Tagged With: 4cmedical, aspectbiosystems, Axonics Modulation Technologies, brainspec, cammed, clinicalsensors, cognitotherapeutics, dayzerodiagnostics, Eyenovia Inc., gel-e, Livongo, Medineering, metavention, patientory, portal instruments, prellisbiologics, reactiverobotics, rxfunction, sonexhealth, spryhealth, startups

SureFire Medical names pharma vet Szela as president, CEO | Personnel Moves – Jan. 26, 2018

January 26, 2018 By Sarah Faulkner

SureFire Medical has named pharma veteran Mary Szela as its president, CEO and board member, succeeding founder James Chomas, who has served as the company’s chief executive and president since 2009. Chomas will assume the role of chief technology officer and oncology strategy officer, focusing his efforts on the the company’s oncology drug-delivery tech. Get the […]

Filed Under: Drug-Device Combinations, Pharmaceutical, Wall Street Beat Tagged With: Aerie Pharmaceuticals, Eyenovia Inc., milestonescientific, oculartherapeutix, PolyPid, Surefire Medical

Eyenovia sets range for IPO

January 10, 2018 By Sarah Faulkner

N.Y.-based startup Eyenovia updated its regulatory filings to reveal that it plans to offer 2.73 million shares priced between $10 – $12 apiece in its initial public offering. The 7-person company, which is developing a device to deliver small doses of drugs to the eye, is applying to list on the Nasdaq exchange under the symbol, “EYEN”. Get the […]

Filed Under: Clinical Trials, Drug-Device Combinations, Funding Roundup, Optical/Ophthalmic, Pharmaceutical Tagged With: Eyenovia Inc.

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS